Milner R J, Pearson J, Nesbit J W, Close P
Onderstepoort Veterinary Academic Hospital, Department of Medicine, Onderstepoort, South Africa.
Onderstepoort J Vet Res. 1996 Dec;63(4):309-13.
Canine malignant lymphoma (CML) is a common lymphoid tumour. Identification of the immunophenotype is of prognostic importance: T-cell lymphomas have a worse prognosis than B-cell lymphomas. Until recently, identification of T- or B-cell lymphomas was undertaken by means of flow cytometry or fluorescent immunocytochemistry on frozen sections. Whilst valid in the research field, these methods are impractical for routine diagnostic histopathology in CML. Commercially available CD3 antibody has been successfully employed in T-cell identification in dogs in formalin-fixed paraffin wax-embedded tissue sections, but the lack of a B-cell marker has been a hindrance until the recent introduction of a commercially available pan-B cell marker, CD79a (DAKO M7051), suitable for diagnostic application upon formalin-fixed paraffin wax-embedded material. Antibody markers to CD3 and CD79a show cross-reactivity across species lines for B cells and T cells respectively. In this group of five selected canine cases, two were identified as B-cell and the other three as T-cell lymphoma, by means of CD3 and CD79a. To the best of our knowledge application of CD79a in cases of CML has not been reported.
犬恶性淋巴瘤(CML)是一种常见的淋巴肿瘤。免疫表型的鉴定具有预后重要性:T细胞淋巴瘤的预后比B细胞淋巴瘤更差。直到最近,T细胞或B细胞淋巴瘤的鉴定是通过对冰冻切片进行流式细胞术或荧光免疫细胞化学来进行的。虽然这些方法在研究领域有效,但对于CML的常规诊断组织病理学来说并不实用。市售的CD3抗体已成功用于福尔马林固定石蜡包埋组织切片中犬T细胞的鉴定,但直到最近引入一种适用于福尔马林固定石蜡包埋材料诊断应用的市售泛B细胞标志物CD79a(DAKO M7051)之前,缺乏B细胞标志物一直是一个障碍。CD3和CD79a的抗体标志物分别对跨物种的B细胞和T细胞显示交叉反应性。在这组选定的5例犬病例中,通过CD3和CD79a鉴定出2例为B细胞淋巴瘤,另外3例为T细胞淋巴瘤。据我们所知,CD79a在CML病例中的应用尚未见报道。